Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoradiotherapy for Stage IVa Oral Cancer
NCT03923998Phase 1Completed
- Sponsor
- Indrayani Hospital and Cancer Institute
- Start
- Mar 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cisplatin in oral squamous cell carcinoma (OSCC), sponsored by Indrayani Hospital and Cancer Institute. Primary endpoints: Objective Response Rate at 1 year, Disease Free Survival at 2 years and 1 more. Started Mar 2016; status: completed.
02
Drugs
cisplatin
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT03923998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923998.